With a shared purpose, we can realize the true promise of CRISPR and improve healthcare, providing hope to more patients with ...

Rare diseases pose unique challenges in the medical field, often affecting a small but vulnerable population with limited treatment options. The Rare Disease Challenge (RaDiChal) is a groundbreaking ...

A sales partner offered a ray of hope that this company couldn't for itself.

CRISPR's gene therapy, Casgevy, faces operational challenges and stiff competition from Lyfgenia, impacting its market adoption. The initial commercial rollout of gene therapies requires the ...

2023 was an important year for patients with sickle cell disease. Prior to CRISPR, the only cure for the life-long ailment was a bone marrow transplant, which is notoriously dangerous and costly. This ...

The idea of self-amplifying gene editing is to get cells to pass on packages of CRISPR machinery to their neighbours, boosting the effect ...

The CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) and its associated protein (Cas9) system is a genome-editing technology that holds the potential to alleviate multiple ...

Artificial intelligence (AI) isn't the only industry with explosive growth potential.

Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, and author of Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing, discusses the difficulties ...

Nobel laureate Jennifer Doudna, PhD; Matthew Porteus, MD, PhD, and Rodolphe Barrangou, PhD—offer their views on the commercial potential and challenges of genome editing following a rollercoaster 2025 ...